DK2063881T3 - Sammensætning og fremgangsmåde til virksom og sikker administration af halopyruvat til behandlingen af cancer - Google Patents
Sammensætning og fremgangsmåde til virksom og sikker administration af halopyruvat til behandlingen af cancer Download PDFInfo
- Publication number
- DK2063881T3 DK2063881T3 DK07750813.3T DK07750813T DK2063881T3 DK 2063881 T3 DK2063881 T3 DK 2063881T3 DK 07750813 T DK07750813 T DK 07750813T DK 2063881 T3 DK2063881 T3 DK 2063881T3
- Authority
- DK
- Denmark
- Prior art keywords
- halopyruvate
- cancer
- procedure
- effective
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US77365306P | 2006-02-16 | 2006-02-16 | |
| US11/706,868 US7754693B2 (en) | 2006-02-16 | 2007-02-14 | Composition and method for the efficacious and safe administration of halopyruvate for the treatment of cancer |
| PCT/US2007/004001 WO2007097989A2 (en) | 2006-02-16 | 2007-02-15 | A composition and method for the efficacious and safe administration of halopyruvate for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2063881T3 true DK2063881T3 (da) | 2019-08-12 |
Family
ID=38437866
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK07750813.3T DK2063881T3 (da) | 2006-02-16 | 2007-02-15 | Sammensætning og fremgangsmåde til virksom og sikker administration af halopyruvat til behandlingen af cancer |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US7754693B2 (da) |
| EP (1) | EP2063881B1 (da) |
| KR (3) | KR20140098216A (da) |
| DK (1) | DK2063881T3 (da) |
| ES (1) | ES2738983T3 (da) |
| HU (1) | HUE045796T2 (da) |
| PL (1) | PL2063881T3 (da) |
| PT (1) | PT2063881T (da) |
| SI (1) | SI2063881T1 (da) |
| WO (1) | WO2007097989A2 (da) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8324175B2 (en) | 2006-02-16 | 2012-12-04 | Young Hee Ko | Compositions and methods for the treatment of cancer |
| WO2010021750A2 (en) | 2008-08-21 | 2010-02-25 | The Johns Hopkins University | Methods and compositions for administration of 3-halopyruvate and related compounds for the treatment of cancer |
| PL2391363T3 (pl) | 2009-01-29 | 2017-03-31 | Young Hee Ko | Kompozycje i sposoby do leczenia raka |
| JP6552509B2 (ja) | 2014-01-14 | 2019-07-31 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 選択的ａｔｐ阻害剤をカプセル化するシクロデキストリン組成物およびその使用 |
| WO2016025922A1 (en) * | 2014-08-14 | 2016-02-18 | Dana-Farber Cancer Institute, Inc. | Coated particles for drug delivery |
| WO2017079563A1 (en) | 2015-11-06 | 2017-05-11 | The Johns Hopkins University | Methods of treating liver fibrosis by administering 3-bromopyruvate |
| ITUA20161610A1 (it) * | 2016-03-14 | 2017-09-14 | Angela Anna Messina | Composto peptidico farmacologicamente attivo, procedimento per la sua preparazione e suo uso. |
| AT518622A1 (de) * | 2016-04-21 | 2017-11-15 | Hg Pharma Gmbh | Dimerer Komplex aus selektiv deglycosyliertem Vitamin D bindenden Protein (GcMAF) und Cholecalciferol (Calciol) und Verfahren zu dessen Herstellung |
| US10245235B2 (en) * | 2016-12-16 | 2019-04-02 | The Charlotte-Mecklenburg Hospital Authority | Compositions and methods for treating muscular dystrophy and other disorders |
| US10434113B2 (en) | 2016-12-16 | 2019-10-08 | The Charlotte Mecklenburg Hospital Authority | Compositions and methods for treating muscular dystrophy and other disorders |
| US20240299323A1 (en) * | 2020-06-29 | 2024-09-12 | Kodiscovery, Llc | Cellular energy inhibitor formulations for the treatment of pathogenic infections and associated methods |
| CN114149347A (zh) * | 2021-12-10 | 2022-03-08 | 诗玮雅(青岛)生物制药有限公司 | 一种新型蒽醌类衍生物及其合成方法和应用 |
| CN116375769B (zh) * | 2023-03-10 | 2024-12-03 | 云南贵金属实验室有限公司 | 一种双靶点Pt(Ⅳ)抗癌前药及其制备方法和用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5759837A (en) * | 1989-01-17 | 1998-06-02 | John Hopkins University | Chemotherapy for cancer by inhibiting the fatty acid biosynthetic pathway |
| US6031000A (en) * | 1998-06-23 | 2000-02-29 | Iowa State University Research Foundation, Inc. | Composition comprising β-hydroxy-β-methylbutyric acid and at least one amino acid and methods of use |
| US7547673B2 (en) * | 2001-09-13 | 2009-06-16 | The Johns Hopkins University | Therapeutics for cancer using 3-bromopyruvate and other selective inhibitors of ATP production |
| CA2498130A1 (en) * | 2002-09-05 | 2004-03-18 | Invitrogen Corporation | Compositions and methods for synthesizing nucleic acids |
| BRPI0406667A (pt) * | 2003-01-10 | 2005-12-20 | Threshold Pharmaceuticals Inc | Método para o tratamento de câncer, e, formulação terapeuticamente aceitável de 2-dg |
| WO2006020403A2 (en) * | 2004-07-28 | 2006-02-23 | Board Of Regents, The University Of Texas System | 3-halo-2-oxopropionate salts and esters as novel anticancer agents |
-
2007
- 2007-02-14 US US11/706,868 patent/US7754693B2/en active Active
- 2007-02-15 KR KR1020147017776A patent/KR20140098216A/ko not_active Ceased
- 2007-02-15 EP EP07750813.3A patent/EP2063881B1/en active Active
- 2007-02-15 KR KR1020157023102A patent/KR20150103329A/ko not_active Ceased
- 2007-02-15 WO PCT/US2007/004001 patent/WO2007097989A2/en active Application Filing
- 2007-02-15 KR KR1020087022619A patent/KR20090005297A/ko active Application Filing
- 2007-02-15 HU HUE07750813A patent/HUE045796T2/hu unknown
- 2007-02-15 PT PT07750813T patent/PT2063881T/pt unknown
- 2007-02-15 SI SI200732122T patent/SI2063881T1/sl unknown
- 2007-02-15 DK DK07750813.3T patent/DK2063881T3/da active
- 2007-02-15 ES ES07750813T patent/ES2738983T3/es active Active
- 2007-02-15 PL PL07750813T patent/PL2063881T3/pl unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2063881B1 (en) | 2019-05-08 |
| EP2063881A4 (en) | 2012-11-07 |
| WO2007097989A2 (en) | 2007-08-30 |
| KR20150103329A (ko) | 2015-09-09 |
| KR20140098216A (ko) | 2014-08-07 |
| HUE045796T2 (hu) | 2020-02-28 |
| PL2063881T3 (pl) | 2020-03-31 |
| ES2738983T3 (es) | 2020-01-28 |
| US20070203074A1 (en) | 2007-08-30 |
| US7754693B2 (en) | 2010-07-13 |
| KR20090005297A (ko) | 2009-01-13 |
| EP2063881A2 (en) | 2009-06-03 |
| PT2063881T (pt) | 2019-08-26 |
| WO2007097989A3 (en) | 2008-05-02 |
| SI2063881T1 (sl) | 2019-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2063881T3 (da) | Sammensætning og fremgangsmåde til virksom og sikker administration af halopyruvat til behandlingen af cancer | |
| DK2155188T3 (da) | Fremgangsmåder og sammensætninger til behandling af tilbagevendende kræft | |
| DK2322221T3 (da) | Farmaceutisk sammensætning til behandling og forebyggelse af cancer | |
| NO20200775A1 (no) | Fremgangsmåter og sammensetninger for behandling av kreft | |
| DK2340042T3 (da) | Fremgangsmåder og præparater til behandling af cancer | |
| DK2220116T3 (da) | Sammensætninger og fremgangsmåder til terapien og diagnosticeringen af influenza | |
| DK2653873T3 (da) | Sammensætninger og anvendelser til behandling af multipel sklerose | |
| DK2474321T3 (da) | Sammensætninger til behandling af collagenmedierede sygdomme | |
| DK1868579T3 (da) | Farmaceutisk sammensætning omfattende en omega-carboxyaryl sunstitueret diphenylurea til behandling af cancer | |
| DK2154971T3 (da) | Synergistisk farmaceutisk kombination til behandling af cancer | |
| DK2185164T3 (da) | Sammensætning og terapeutisk antitumorvaccine | |
| DK2101819T3 (da) | Fremgangsmåder, sammensætninger og kits til behandling af smerte og pruritis | |
| DK2368550T3 (da) | Androgenreceptormodulator til behandlingen af prostatakræft og androgenreceptor-associerede sygdomme | |
| BRPI0917444A2 (pt) | composições farmacêuticas de retenção gástrica para o tratamento e prevenção de doenas do snc | |
| DK2195015T3 (da) | Sammensætning til behandling af prostatacancer | |
| DK2131856T3 (da) | Sammensætninger og fremgangsmåder til forebyggelsen og behandlingen af autoimmune tilstande | |
| DK2114419T3 (da) | Natriummetaarsenit til anvendelse i behandling af smerte og inflammation | |
| DK2073811T3 (da) | Kinaseinhibitorer anvendelige til behandling af myeloproliferative sygdomme og andre proliferative sygdomme | |
| ZA200904492B (en) | Compositions and methods for the treatment of infections and tumors | |
| DK2056842T3 (da) | Modificeret galactosylceramid til behandling af cancerøse sygdomme | |
| DK2235002T3 (da) | 4-pyridinonforbindelser og anvendelse heraf til behandling af cancer | |
| DK3300601T3 (da) | Faste lægemiddelforhold til behandling af hæmatopoietiske kræftformer og proliferative lidelser | |
| DK2109432T3 (da) | Behandlingssystem til repositionering af patient og legemsdel | |
| DK1771201T3 (da) | Sammensætninger og fremgangsmåder til behandling eller forebyggelse af oxalat-relateret sygdom | |
| IL196843A0 (en) | Compositions and methods for the treatment of radiation proctosigmoitis |